MMJ Observer
Tag Archives: GW Pharmaceuticals PLC- ADR

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) happens to be a biopharmaceutical provider focusing on the discovery, development as well as the commercialization of a wide spectrum of therapeutics from its proprietary cannabinoid product platform. The...

By Jon Slotnick on Apr 19th, 2017
GW Pharmaceuticals

GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) CEO Justin Gover will present at the upcoming Cowen and Company Annual Healthcare Conference on March 8, 2017. Several new drugs and therapies are being advanced at a rapidly increasing pace in the Cannabidiol...

By Emily Gibson on Mar 7th, 2017
GW Pharmaceuticals

Goldman Sachs initiated coverage on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) with a “Buy” rating and price target of $189. Four other groups lately updated their coverage. The target range as noted from the released reports is from $135...

By Emily Gibson on Jan 30th, 2017
GW Pharmaceuticals

The American Epilepsy Society’s 70th Annual Meeting was an important one for GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), as it sent off 2016 with its positive Epidiolex® (cannabidiol or CBD) Phase 3 data. The company said that the data it...

gw-pharmaceuticals

Justin Gover, the CEO of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), said that in FY2016, the company has closed three promising Phase III studies for Epidiolex in subjects with two different rare cure resistant types of childhood-onset epilepsy...

By Elizabeth Jackson on Dec 21st, 2016

Much has been inferred of the market prospect for “Epidiolex” from GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH). All the merited delight over the “Epidiolex” potential in the cure of childhood epilepsies has blinded the...

By Emily Gibson on Dec 15th, 2016